Cannabis and psychosis - A review;Cannabis und psychosen - Eine übersicht

Praxis

Volumn 93, Issue 23, 2004, Pages 997-1002

  Schaub, M ^a   Rossler W ^a   Stohler, R ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Cannabis; Psychosis; Schizophrenia spectrum disorders; Substance use disorders

Indexed keywords

CANNABINOID;

CANNABIS ADDICTION; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DOSE RESPONSE; HUMAN; PSYCHOSIS; REVIEW; RISK; SCHIZOPHRENIA; SWITZERLAND;

CANNABINOIDS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MARIJUANA ABUSE; PSYCHOSES, SUBSTANCE-INDUCED; RISK; SCHIZOPHRENIA; SWITZERLAND;

EID: 2942621966     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.93.23.997     Document Type: Review

References (38)

1. SFDRS (2002). Exklusiver Hanftest: Stoff wird immer stärker. Sendung Kassensturz 26.11.2002 [online]. Available: http://www.sfdrs.ch/sendungen/ kassensturz/index.html.
2. Müller S, Gmel G. Veränderungen des Einstiegsalters in den Cannabiskonsum: Ergebnisse der zweiten Schweizer Gesundheitsbefragung 1997. Sozial- und Präventivmedizin 2002; 47: 1-10.
3. Dewane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13. (Pubitemid 19007296)
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-64.
5. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-49. (Pubitemid 23026736)
6. Bühler B, Hambrecht M, Löffler W, an der Heiden W, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54: 243-51. (Pubitemid 34304217)
7. Cantwell R. Substance use and schizophrenia: effects on symptoms, social functioning and service use. Br J Psychiatry 2003; 182: 324-29. (Pubitemid 36408284)
8. Degenhardt L, Hall W. Cannabis and Psychosis. Curr Psychiatry Rep 2002; 4: 191-96.
9. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993; 163: 141-49. (Pubitemid 23233080)
10. Chopra G, Smith J. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry 1974; 30: 24-27.
11. McGuire PK, Jones P, Harvey I et al. Cannabis and acute psychosis. Schizophr Res 1995; 13: 161-67. (Pubitemid 24330925)
12. Thornicroft G. Cannabis and psychosis - is there epidemiological evidence for an association? Br J Psychiatry 1990; 157: 25-33. (Pubitemid 20208657)
13. Basu D, Malhorta A, Bhagat A, Varma VK. Cannabis psychosis and acute schizophrenia. A case-control study from India. Eur Addict Res 1999; 5: 71-73. (Pubitemid 29312950)
14. Hall W, Degenhardt L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust N Z J Psychiatry 2000; 34: 26-34. (Pubitemid 34692842)
15. Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2001; 36: 338-42. (Pubitemid 32894736)
16. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an 'ultra' highrisk group. Aust N Z J Psychiatry 2002; 36: 800-06. (Pubitemid 35469740)
17. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-79. (Pubitemid 24127299)
18. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and Schizophrenia: A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-86.
19. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br Med J 2002; 23: 325(7374): 1199.
20. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319-27. (Pubitemid 34857999)
21. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J 2002; 23: 1212-13. (Pubitemid 35398785)
22. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. Br Med J 2002; 325: 1195-98. (Pubitemid 35398781)
23. Martinez-Arevalo MJ, Calcedo-Ordonez A & Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994; 164: 679-81. (Pubitemid 24161269)
24. Jablensky A, Sartorius N, Ernberg G et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization tencountry study. Psychol Med Monogr Suppl 1992; 20: 1-97.
25. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ (1991). Drug Abuse in Schizophrenic Patients: Clinical Correlates and Reasons for Use. Am J Psychiatry1991; 148: 224-30.
26. Hanus L, Abu-Lafi S, Fride E et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-65. (Pubitemid 32249827)
27. Glass M. The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 743-65. (Pubitemid 32374965)
28. Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 2001; 48: 83-92. (Pubitemid 32241185)
29. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-78.
30. Giuffrida A, Parson LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamin activation of endogenous cannabinod signaling in dorsal striatum. Nat Neurosci 1999; 2: 358-63. (Pubitemid 30491279)
31. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 6651-69.
32. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP- 55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103: 9-15. (Pubitemid 32304342)
33. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psych Res 2001; 107: 173-77. (Pubitemid 32868802)
34. O'Leary DS, Block RI, Koeppel JA et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002; 26: 802-16. (Pubitemid 34455033)
35. Leroy S, Griffon N, Bourdel MC, Olié JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): Association study using a single-base polymorphism in coding exon 1. Am J Med Genet 2001; 105: 749-52. (Pubitemid 33101476)
36. Fritzsche M. Lateral gene transfer of foreign DNA: The missing link between cannabis psychosis and schizophrenia. Am J Med Genet 2002; 114: 512-15. (Pubitemid 34680576)
37. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. PNAS 2003; 100: 1393-98. (Pubitemid 36184012)
38. Schneider U, Müller-Vahl KR, Stuhrmann M et al. Die Bedeutung des endogenen Cannabinoidsystems bei verschiedenen neuropsychiatrischen Erkrankungen. Fortschreitende Neurologische Psychiatrie 2000; 68: 433-38.